A blood test has been shown to accurately identify patients with amyotrophic lateral sclerosis at early stages, which could ...

A highly accurate diagnostic blood test has been developed for amyotrophic lateral sclerosis (ALS), a progressive ...

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is the most common degenerative motor neuron disease ...

Launched in 2020 to more quickly bring to market an effective medicine for amyotrophic lateral sclerosis, the HEALEY Platform ...

Neuralink rival Synchron is connecting its brain–computer interface with consumer technologies to allow people with paralysis ...

People with rare genetic variants linked to degenerative brain disorders like Parkinson's disease are at increased risk of ...

The Phase 1 clinical trial is expected to enroll about 60 participants to test how safe and well tolerated multiple doses of ...

For CNM-Au8, Clene has more than 700 patient-years of safety data that show no significant safety concerns or safety trends identified. No serious adverse events (SAEs) have been identified as related ...

Siplizumab is under clinical development by ITB-Med and currently in Phase I for Amyotrophic Lateral Sclerosis.

Fasudil is under clinical development by Woolsey Pharmaceuticals and currently in Phase II for Amyotrophic Lateral Sclerosis.

China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal administration of PolTREG’s PTG-007 Treg cell therapy to ...